# DDY391 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/ddy391

> The next catalyst for DDY391, sponsored by NOVARTIS AG (NVS), is its topline data readout, Dec 2028 to Mar 2029.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | DDY391 |
| Codes | DDY391 |
| Sponsor | NOVARTIS AG (NVS) https://sec-api.dev/companies/nvs/catalysts |
| Indications | [Moderate to Severe Psoriatic Arthritis](https://sec-api.dev/indications/moderate-to-severe-psoriatic-arthritis), [Sjögren's Disease](https://sec-api.dev/indications/sjogren-s-disease) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Dec 2028 to Mar 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Moderate to Severe Psoriatic Arthritis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07801495 (A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-12-13 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT07801495

### December 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Moderate to Severe Psoriatic Arthritis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07801495 (A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-12-13 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT07801495

### Feb to May 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Sjögren's Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07737743 (A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-02-19 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT07737743

### February 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Sjögren's Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07737743 (A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-02-19 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT07737743

### Dec 2029 to Mar 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Moderate to Severe Psoriatic Arthritis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07923773 (Extension Study of Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis (CDDY391A12201-extension)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2029-12-12 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT07923773

### December 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Moderate to Severe Psoriatic Arthritis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07923773 (Extension Study of Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis (CDDY391A12201-extension)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2029-12-12 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT07923773

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/ddy391.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "DDY391 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/ddy391

```bibtex
@misc{secapidev_pdufa_ddy391_20261116,
  title        = {DDY391 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/ddy391}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_ddy391_20261116","title":"DDY391 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/ddy391","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
